Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24591799 | 0.97 | SIRT6 (0.35) | C3AR1MEN1GAAKMT2ASIRT6 | |
| SCHEMBL4572264 | 0.88 | NPY4R (0.36) | MEN1GAAKMT2ASIRT6SIRT1 | |
| SCHEMBL26880961 | 0.88 | NPY4R (0.36) | MEN1GAAKMT2ASIRT6SIRT1 | |
| SCHEMBL25100471 | 0.85 | C3AR1 (0.44) | C3AR1MEN1GAAKMT2ACTDSP1 | |
| SCHEMBL19483434 | 0.84 | ALOX15 (0.36) | MEN1KMT2ASIRT6SIRT1FOLH1 | |
| SCHEMBL19483435 | 0.84 | ALOX15 (0.36) | MEN1KMT2ASIRT6SIRT1FOLH1 | |
| SCHEMBL22139606 | 0.84 | NPY4R (0.39) | FOLH1 | |
| SCHEMBL20997114 | 0.84 | NPY4R (0.39) | FOLH1 | |
| SCHEMBL26559128 | 0.84 | MEN1 (0.31) | MEN1GAAKMT2A | |
| SCHEMBL21013102 | 0.82 | FURIN (0.32) | C3AR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | C3AR1 419/4885MEN1 2331/4885GAA 2471/4885 |
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | C3AR1 117/4885MEN1 2520/4885GAA 59/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | C3AR1 213/4885MEN1 1665/4885GAA 2307/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | C3AR1 117/4885MEN1 2520/4885GAA 59/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | C3AR1 117/4885MEN1 2520/4885GAA 59/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | C3AR1 29/4885MEN1 1417/4885GAA 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.